Anti-cancer Drugs

杂志介绍

Anti-cancer Drugs杂志介绍

《Anti-cancer Drugs》是一本以English为主的未开放获取国际优秀期刊，中文名称抗癌药，本刊主要出版、报道医学-ONCOLOGY领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为1.8，最新CiteScore 指数为3.8。

本刊近期中国学者发表的论文主要有：

• MiR-302c-5p affects the stemness and cisplatin resistance of nasopharyngeal carcinoma cells by regulating HSP90AA1

  Author: Zhou, Xiangqi; Zheng, Le; Zeng, Chunya; Wu, Yangjie; Tang, Xiyang; Zhu, Yuan; Tang, Sanyuan

• Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer

  Author: Zhang, Xiaoyi; Hong, Shasha; Yang, Jiang; Liu, Jingchun; Wang, Ying; Peng, Jiaxin; Wang, Haoyu; Hong, Li

• Hsa_circ_0007380 silencing restrains the growth and enhances radiosensitivity in esophagus cancer by miR-644a/Spindlin 1 axis

  Author: Yu, Weihui; Ning, Ke; Xiao, Jincheng; Bai, Qiwen; Guo, Chenyang

• Circ-ABCC4 contributes to prostate cancer progression and radioresistance by mediating miR-1253/SOX4 cascade

  Author: Yu, Tao; Du, Hong; Sun, Changhai

英文介绍

Anti-cancer Drugs杂志英文介绍

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.